VanEck Biotech ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
VanEck Biotech ETF BBH
Morningstar’s Analysis BBH
Will BBH outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the BBH management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of BBH’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 69.2
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Amgen Inc | 14.34 | 51M | Healthcare |
Gilead Sciences Inc | 13.10 | 47M | Healthcare |
Vertex Pharmaceuticals Inc | 8.08 | 29M | Healthcare |
argenx SE ADR | 6.40 | 23M | Healthcare |
Regeneron Pharmaceuticals Inc | 6.01 | 21M | Healthcare |
IQVIA Holdings Inc | 4.72 | 17M | Healthcare |
Natera Inc | 4.43 | 16M | Healthcare |
Revolution Medicines Inc Ordinary Shares | 4.36 | 16M | Healthcare |
Biogen Inc | 4.05 | 14M | Healthcare |
Alnylam Pharmaceuticals Inc | 3.71 | 13M | Healthcare |
United States